Lalit Mohan Negi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lalit Mohan Negi has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Sushama Talegaonkar
Department of Pharmaceutics, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, New Delhi, India
7 shared publications Manu Jaggi
Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, New Delhi 110062, India
4 shared publications- Farhan Jalees Ahmad
Department of Pharmaceutics, School of Pharmaceutical Education and Research, New Delhi, India
2 shared publications - Meenakshi Chauhan
Department of Pharmaceutics , Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), University of Delhi , Pushp Vihar, Sector 3, New Delhi 110017 , India
2 shared publications Roop K. Khar
Department of Pharmaceutics, Jamia Hamdard, New Delhi, India
2 shared publicationsZeenat Iqbal
Department of Pharmaceutics, Jamia Hamdard, New Delhi, India
2 shared publications
Latest Publications
- 1 February 2014
- Published by Elsevier in Medical Hypotheses
- Vol. 82 (2) , 240-242
Addressing the potential toxicities of the non-specific P-glycoprotein modulation by amalgamation with targeted approach in MDR tumors
- 1 February 2014
- Published by Elsevier in Medical Hypotheses
- Vol. 82 (2) , 240-242
Addressing the potential toxicities of the non-specific P-glycoprotein modulation by amalgamation with targeted approach in MDR tumors
- 1 January 2014
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 461 (1-2) , 403-410
Development of protocol for screening the formulation components and the assessment of common quality problems of nano-structured lipid carriers
- 1 January 2014
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 461 (1-2) , 403-410
Development of protocol for screening the formulation components and the assessment of common quality problems of nano-structured lipid carriers
- 1 November 2013
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 111, 346-353
Nano scale self-emulsifying oil based carrier system for improved oral bioavailability of camptothecin derivative by P-Glycoprotein modulation
- 1 November 2013
- Published by Elsevier in Colloids and Surfaces B: Biointerfaces
- Vol. 111, 346-353
Nano scale self-emulsifying oil based carrier system for improved oral bioavailability of camptothecin derivative by P-Glycoprotein modulation
- Open Access
- 1 July 2013
- Published by Taylor & Francis in Journal of Experimental Nanoscience
- Vol. 8 (5) , 657-669
Nano-appended transdermal gel of Tenoxicam via ultradeformable drug carrier system
Tenoxicam is one of the potent non-steroidal anti-inflammatory drugs (NSAIDs), which is used clinically in the treatment of rheumatoid arthritis. Like other NSAIDs, Tenoxicam also suffers from the drawback of being associated with gastrointestinal side effects. Further, transdermal penetration of this drug is very poor, which circumvents the use of transdermal route. The main objective of this study is to exploit the concept of ultradeformable vesicles to increase the transport of Tenoxicam through transdermal route, and also to present it as a possible replacement for the oral NSAID therapy for rheumatoid arthritis. Three concentrations (5%, 15% and 25%) of three different surfactants (Tween-80, Span-80 and sodium desoxycholate) were used along with soya lecithin to prepare the ultradeformable vesicles. Among nine different types of vesicles, T3 vesicles (with 25% Tween-80) were found to have shown the smallest size (82.80 ± 0.74 nm), highest release in 24 h (98.01 ± 0.33%) and highest deformability (31.27 ± 0.28) and hence chosen for formulating into the gel. Among three different Carbopol® 934 concentrations (1%, 1.5% and 2%), G-2 with 1.5% carbopol was chosen as the final formulation. The formulation has shown almost twice the transdermal flux as compared to the gel with free Tenoxicam. The in vivo performance was also found to be significantly better than the oral Tenoxicam and marketed aceclofenac gel (Hifenac®). This study concluded that the gel containing Tenoxicam encapsulated in ultradeformable vesicles has a better prospective for the transdermal use to treat rheumatoid arthritis.
- 1 July 2013
- Published by Taylor & Francis in Journal of Experimental Nanoscience
- Vol. 8 (5) , 657-669
Open AccessNano-appended transdermal gel of Tenoxicam via ultradeformable drug carrier system
Tenoxicam is one of the potent non-steroidal anti-inflammatory drugs (NSAIDs), which is used clinically in the treatment of rheumatoid arthritis. Like other NSAIDs, Tenoxicam also suffers from the drawback of being associated with gastrointestinal side effects. Further, transdermal penetration of this drug is very poor, which circumvents the use of transdermal route. The main objective of this study is to exploit the concept of ultradeformable vesicles to increase the transport of Tenoxicam through transdermal route, and also to present it as a possible replacement for the oral NSAID therapy for rheumatoid arthritis. Three concentrations (5%, 15% and 25%) of three different surfactants (Tween-80, Span-80 and sodium desoxycholate) were used along with soya lecithin to prepare the ultradeformable vesicles. Among nine different types of vesicles, T3 vesicles (with 25% Tween-80) were found to have shown the smallest size (82.80 ± 0.74 nm), highest release in 24 h (98.01 ± 0.33%) and highest deformability (31.27 ± 0.28) and hence chosen for formulating into the gel. Among three different Carbopol® 934 concentrations (1%, 1.5% and 2%), G-2 with 1.5% carbopol was chosen as the final formulation. The formulation has shown almost twice the transdermal flux as compared to the gel with free Tenoxicam. The in vivo performance was also found to be significantly better than the oral Tenoxicam and marketed aceclofenac gel (Hifenac®). This study concluded that the gel containing Tenoxicam encapsulated in ultradeformable vesicles has a better prospective for the transdermal use to treat rheumatoid arthritis.
- 7 December 2012
- Published by IOP Publishing in Nanotechnology
- Vol. 24 (1) , 015104
A logical approach to optimize the nanostructured lipid carrier system of irinotecan: efficient hybrid design methodology
Development of an effective formulation involves careful optimization of a number of excipient and process variables. Sometimes the number of variables is so large that even the most efficient optimization designs require a very large number of trials which put stress on costs as well as time. A creative combination of a number of design methods leads to a smaller number of trials. This study was aimed at the development of nanostructured lipid carriers (NLCs) by using a combination of different optimization methods. A total of 11 variables were first screened using the Plackett-Burman design for their effects on formulation characteristics like size and entrapment efficiency. Four out of 11 variables were found to have insignificant effects on the formulation parameters and hence were screened out. Out of the remaining seven variables, four (concentration of tween-80, lecithin, sodium taurocholate, and total lipid) were found to have significant effects on the size of the particles while the other three (phase ratio, drug to lipid ratio, and sonication time) had a higher influence on the entrapment efficiency. The first four variables were optimized for their effect on size using the Taguchi L9 orthogonal array. The optimized values of the surfactants and lipids were kept constant for the next stage, where the sonication time, phase ratio, and drug:lipid ratio were varied using the Box-Behnken design response surface method to optimize the entrapment efficiency. Finally, by performing only 38 trials, we have optimized 11 variables for the development of NLCs with a size of 143.52 ± 1.2 nm, zeta potential of -32.6 ± 0.54 mV, and 98.22 ± 2.06% entrapment efficiency.
- 7 December 2012
- Published by IOP Publishing in Nanotechnology
- Vol. 24 (1) , 015104
A logical approach to optimize the nanostructured lipid carrier system of irinotecan: efficient hybrid design methodology
Development of an effective formulation involves careful optimization of a number of excipient and process variables. Sometimes the number of variables is so large that even the most efficient optimization designs require a very large number of trials which put stress on costs as well as time. A creative combination of a number of design methods leads to a smaller number of trials. This study was aimed at the development of nanostructured lipid carriers (NLCs) by using a combination of different optimization methods. A total of 11 variables were first screened using the Plackett-Burman design for their effects on formulation characteristics like size and entrapment efficiency. Four out of 11 variables were found to have insignificant effects on the formulation parameters and hence were screened out. Out of the remaining seven variables, four (concentration of tween-80, lecithin, sodium taurocholate, and total lipid) were found to have significant effects on the size of the particles while the other three (phase ratio, drug to lipid ratio, and sonication time) had a higher influence on the entrapment efficiency. The first four variables were optimized for their effect on size using the Taguchi L9 orthogonal array. The optimized values of the surfactants and lipids were kept constant for the next stage, where the sonication time, phase ratio, and drug:lipid ratio were varied using the Box-Behnken design response surface method to optimize the entrapment efficiency. Finally, by performing only 38 trials, we have optimized 11 variables for the development of NLCs with a size of 143.52 ± 1.2 nm, zeta potential of -32.6 ± 0.54 mV, and 98.22 ± 2.06% entrapment efficiency.
- 4 July 2012
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 20 (7) , 561-573
Role of CD44 in tumour progression and strategies for targeting
CD44 or hyaluronan receptor is a transmembrane receptor associated with aggressive tumour growth, proliferation, and metastasis. In normal physiology, this receptor has a crucial role in cell adhesion, inflammation, and repair processes. However, many tumour cells over-express this receptor and abuse it to become progressive and perpetual units. The article comments from common functioning of the CD44 receptor, to its diabolic multi-dimensional effects in promotion of malignant cells. It also illuminates the relations of CD44 endorsed processes with other biomolecular events in cancer progression. In an end, the review focuses comprehensively at ongoing researches to exploit the CD44 over-expression as a probable target in treatment, management, and diagnosis of malignancy.
- 4 July 2012
- Published by Taylor & Francis in Journal of Drug Targeting
- Vol. 20 (7) , 561-573
Role of CD44 in tumour progression and strategies for targeting
CD44 or hyaluronan receptor is a transmembrane receptor associated with aggressive tumour growth, proliferation, and metastasis. In normal physiology, this receptor has a crucial role in cell adhesion, inflammation, and repair processes. However, many tumour cells over-express this receptor and abuse it to become progressive and perpetual units. The article comments from common functioning of the CD44 receptor, to its diabolic multi-dimensional effects in promotion of malignant cells. It also illuminates the relations of CD44 endorsed processes with other biomolecular events in cancer progression. In an end, the review focuses comprehensively at ongoing researches to exploit the CD44 over-expression as a probable target in treatment, management, and diagnosis of malignancy.
- 1 January 2012
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 422 (1-2) , 436-444
Oil based nanocarrier system for transdermal delivery of ropinirole: A mechanistic, pharmacokinetic and biochemical investigation
- 1 January 2012
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 422 (1-2) , 436-444
Oil based nanocarrier system for transdermal delivery of ropinirole: A mechanistic, pharmacokinetic and biochemical investigation